Star Imaging FY26 PAT rises 21% to ₹19.3 crore
Star Imaging and Path Lab Limited reported a 21% increase in net profit to ₹19.3 crore for FY26, with revenue rising 6% to ₹88.5 crore. EBITDA increased 17% to ₹33.2 crore, and the company utilized ₹4,053.60 lakhs of its IPO proceeds. Management guided for 25%-30% growth in FY27, with capex estimated between ₹20 crore and ₹25 crore.
*this image is generated using AI for illustrative purposes only.
Star Imaging and Path Lab Limited has reported a 21% increase in net profit to ₹19.3 crore for the financial year ended March 31, 2026, up from ₹15.9 crore in the prior year. The Board of Directors approved the standalone and consolidated financial results during a meeting held on May 22, 2026. Following the announcement, the company made the audio recording of its earnings call, held on May 25, 2026, available for stakeholders.
Financial Performance
Revenue from operations for the full year stood at ₹88.5 crore, compared to ₹83.2 crore in the previous year. For the half year ended March 31, 2026, the net profit was recorded at ₹9.2 crore on total revenue of ₹43.3 crore. The earnings per share (EPS) for the full year was reported at ₹11.09 on a basic and diluted basis.
| Metric | Year Ended March 31, 2026 (₹ in Lakhs) | Year Ended March 31, 2025 (₹ in Lakhs) |
|---|---|---|
| Revenue from Operations | 8850.00 | 8320.00 |
| Total Revenue | 8952.81 | 8351.74 |
| Total Expenses | 6320.30 | 5219.30 |
| Profit for the Year | 1930.00 | 1590.00 |
| Basic EPS (₹) | 11.09 | 11.79 |
Operational Highlights
Star Imaging's EBITDA for FY26 stood at ₹33.2 crore, a 17% increase from the previous year, with an EBITDA margin of 37.5%. The company operates 24 diagnostic centers and continues to expand its footprint in Delhi, Uttar Pradesh, and Maharashtra. The investor presentation highlighted a reclassification of one business segment from B2C to B2B to reflect accurate operational data.
IPO Proceeds Utilization
The company disclosed the utilization of its Initial Public Offering (IPO) proceeds, which totaled ₹5,566.40 lakhs. As of March 31, 2026, the company had utilized ₹4,053.60 lakhs. The primary allocations included meeting working capital requirements (₹2,500.00 lakhs), loan repayment (₹1,200.00 lakhs), and the purchase of medical equipment (₹514.08 lakhs). The balance proceeds yet to be utilized amounted to ₹1,512.80 lakhs.
Auditor's Report
M/s. BHS & Co, Statutory Auditors of the company, issued an audit report with an unmodified opinion on the audited financial results for both standalone and consolidated statements. The report confirms that the financial results give a true and fair view of the company's financial performance in conformity with Indian Accounting Standards.
Future Outlook
Management expressed confidence in delivering 25%-30% growth in FY27, following regulatory delays that impacted execution in FY26. The company plans to expand its diagnostic centre footprint and deepen capabilities in molecular diagnostics and advanced imaging. Capital expenditure for FY27 is estimated between ₹20 crore and ₹25 crore, primarily for equipment purchase and construction.
Historical Stock Returns for Star Imaging And Path Lab
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.33% | +7.26% | +10.39% | -19.94% | -36.08% | -36.08% |
How will the planned ₹20-25 crore capital expenditure specifically impact capacity utilization and revenue growth in FY27?
What strategic benefits does the reclassification of the business segment from B2C to B2B offer for future operational scalability?
How does the company intend to sustain its 25%-30% growth target given the 6% decline in Basic EPS year-over-year?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
